Published in Cancer Gene Ther on November 01, 2005
Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods (2010) 1.48
CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med (2007) 0.99
Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia (2014) 0.90
Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors. J Virol (2006) 0.88
Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol (2006) 0.85
Immune cell recruitment and cell-based system for cancer therapy. Pharm Res (2007) 0.83
PLGA-carbon nanotube conjugates for intercellular delivery of caspase-3 into osteosarcoma cells. PLoS One (2013) 0.80
Influence of vector design and host cell on the mechanism of recombination and emergence of mutant subpopulations of replicating retroviral vectors. BMC Mol Biol (2009) 0.78
APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem (2006) 3.30
Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature (2011) 2.94
Targeted cell entry of lentiviral vectors. Mol Ther (2008) 2.34
Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem (2004) 2.33
The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci U S A (2005) 1.95
Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol (2008) 1.63
T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood (2012) 1.55
Specific gene delivery to liver sinusoidal and artery endothelial cells. Blood (2013) 1.51
Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods (2010) 1.48
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Mol Ther Nucleic Acids (2013) 1.45
European regulation tackles tissue engineering. Nat Biotechnol (2007) 1.42
Multivalent antibodies: when design surpasses evolution. Trends Biotechnol (2010) 1.28
Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Trends Biotechnol (2009) 1.18
Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin (2005) 1.14
Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet. J Biol Chem (2008) 1.12
Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes. J Biol Chem (2010) 1.12
Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res (2006) 1.12
DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther (2011) 1.08
Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res (2013) 1.05
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther (2011) 1.02
In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One (2009) 1.02
Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther (2002) 1.00
Multiple restrictions of human immunodeficiency virus type 1 in feline cells. J Virol (2007) 1.00
Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol (2004) 0.99
Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s). J Virol (2002) 0.98
Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol (2009) 0.98
Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucleic Acids Res (2007) 0.97
Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res (2005) 0.97
The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus. J Gen Virol (2003) 0.97
Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells. Virology (2007) 0.97
Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj. PLoS One (2009) 0.96
A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J (2003) 0.94
Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP. J Virol (2005) 0.94
Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol (2003) 0.94
Model structure of APOBEC3C reveals a binding pocket modulating ribonucleic acid interaction required for encapsidation. Proc Natl Acad Sci U S A (2009) 0.94
The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. J Biol Chem (2010) 0.94
Identification of R-peptides in envelope proteins of C-type retroviruses. J Gen Virol (2002) 0.93
Enhanced antiangiogenic therapy with antibody-collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events. Int J Cancer (2006) 0.92
Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther (2012) 0.92
Functional improvement of antibody fragments using a novel phage coat protein III fusion system. Biochem Biophys Res Commun (2002) 0.90
Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies. Proc Natl Acad Sci U S A (2013) 0.90
Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol Ther (2006) 0.89
A global regulatory science agenda for vaccines. Vaccine (2013) 0.89
DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther (2013) 0.88
Stable transduction of primary human monocytes by simian lentiviral vector PBj. Mol Ther (2005) 0.88
Lymphocyte display: a novel antibody selection platform based on T cell activation. PLoS One (2009) 0.88
Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective. J Immunother (2006) 0.87
Development of a computer-assisted high-throughput screening platform for anti-angiogenic testing. Microvasc Res (2002) 0.86
Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies. J Immunol (2007) 0.86
The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. Blood (2005) 0.86
Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems. Mol Biotechnol (2011) 0.85
Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles. J Virol (2005) 0.85
The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Methods Mol Biol (2009) 0.85
Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol (2009) 0.85
The heterotrimeric laminin coiled-coil domain exerts anti-adhesive effects and induces a pro-invasive phenotype. PLoS One (2012) 0.85
Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS One (2012) 0.85
Genetic engineering of onco/lentivirus hybrids results in formation of infectious but not of replication-competent viruses. J Gen Virol (2004) 0.83
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol (2013) 0.83
Prototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3G. J Virol (2013) 0.83
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology (2012) 0.83
Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J (2005) 0.83
Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR. Clin Cancer Res (2008) 0.82
Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all? Curr Gene Ther (2005) 0.82
The receptor attachment function of measles virus hemagglutinin can be replaced with an autonomous protein that binds Her2/neu while maintaining its fusion-helper function. J Virol (2013) 0.82
Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. Cancer Res (2010) 0.82
Antibody gene therapy: getting closer to clinical application? Curr Gene Ther (2013) 0.81
Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology (2006) 0.80
Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM. Virology (2011) 0.80
Cell type specific gene delivery by lentiviral vectors: New options in immunotherapy. Oncoimmunology (2013) 0.80
The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. Trends Mol Med (2003) 0.80
CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes. PLoS One (2013) 0.80
Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes. J Mol Med (Berl) (2003) 0.80
Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein. Cancer Gene Ther (2002) 0.80
Coreceptor Switch of [MLV(SIVagm)] pseudotype vectors by V3-loop exchange. Virology (2002) 0.79
Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes. J Virol (2002) 0.79
Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques. Hum Gene Ther Clin Dev (2013) 0.79
Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells. Cancer Gene Ther (2005) 0.79
Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases. J Virol (2011) 0.79
Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold. J Gene Med (2006) 0.78
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol Ther (2012) 0.78
Interaction of human immunodeficiency virus type 1 Vif with APOBEC3G is not dependent on serine/threonine phosphorylation status. J Gen Virol (2012) 0.78
CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells. Stem Cells Dev (2015) 0.77